Oxaliplatin Teva

Oxaliplatin, the active ingredient in Oxaliplatin Teva, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of certain solid tumours, most notably colorectal cancer, and is administered under the supervision of oncologists.

GNH USA supplies Oxaliplatin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Teva is a platinum‑based chemotherapeutic that interferes with DNA replication in malignant cells. - Colorectal cancer: enhances survival when combined with fluoropyrimidine‑based regimens. - Gastric cancer: used as part of combination therapy for advanced disease. - Pancreatic cancer: contributes to tumour response in multi‑drug protocols.

Adverse reactions to Oxaliplatin Teva are observed across a range of severity.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, often dose‑related. - Nausea and vomiting: may require anti‑emetic prophylaxis. - Diarrhoea: typically mild to moderate. - Fatigue: generalized tiredness during treatment cycles. - Thrombocytopenia: reduced platelet count observed in blood tests. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Severe peripheral neuropathy: persistent sensory loss. - Acute hypersensitivity reactions: flushing, dyspnoea, hypotension. - Hemolytic‑type anemia: sudden drop in haemoglobin. - Cardiac arrhythmias: irregular heart rhythm episodes. - Renal impairment: worsening kidney function. - Cytopenias affecting multiple lineages: pancytopenia.

When handling Oxaliplatin Teva, clinicians should observe specific safety measures. - Renal function monitoring: assess creatinine clearance before each cycle. - Hepatic function assessment: check liver enzymes regularly. - Neuropathy assessment: evaluate sensory changes at each visit. - Premedication with anti‑emetics: reduce nausea and vomiting risk. - Avoid concurrent neurotoxic agents: limit additive neuropathy risk. - Store at below 25°C: keep in original container, protect from light and moisture.

Oxaliplatin may interact with several concomitant medicines.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increase risk of nephrotoxicity. - High‑dose vitamin C: may reduce platinum‑drug efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other neurotoxic chemotherapies: additive peripheral neuropathy. - CYP‑mediated drugs: potential pharmacokinetic alterations. - Loop diuretics: may affect renal clearance of the drug.